Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ImmunoPrecise Antibodies ( (IPA) ) has shared an announcement.
ImmunoPrecise Antibodies Ltd. announced its successful application to transfer its securities to the Nasdaq Capital Market, gaining an additional 180-day period to comply with the minimum bid price requirement. This move ensures the company’s continued Nasdaq listing as it progresses with its strategic initiatives, impacting its operational and market positioning.
More about ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd. is a biotherapeutic research and technology company that specializes in AI-driven antibody discovery and development. Through its subsidiaries, the company provides an end-to-end solution for developing next-generation antibody therapeutics, using systems biology, multi-omics modeling, and artificial intelligence to discover highly specialized therapeutic antibodies for challenging disease targets.
YTD Price Performance: -4.44%
Average Trading Volume: 6,406,201
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $19.72M
See more data about IPA stock on TipRanks’ Stock Analysis page.